CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...

An update from Wave Life Sciences ( (WVE)) is now available. On December 9, 2025, Wave Life Sciences announced an underwritten public offering of 15,789,475 ordinary shares at $19.00 per share and pre ...

Wave Life Sciences (WVE) “announced that it has commenced an underwritten public offering of $250 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ...

The $400M at-the-market equity offering was completed in just over two weeks. The average sale price in the offering was at a 149% premium compared to the company’s previous ATM raise in January 2025.

D-Wave Quantum Inc (NYSE:QBTS) shares are trading higher. The company on Tuesday announced the successful completion of its at-the-market offering. What Happened: D-Wave said it successfully sold $400 ...

PALO ALTO, Calif.--(BUSINESS WIRE)--D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), a leader in quantum computing systems, software, and services and the world’s first commercial ...

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...

Company sees increased interest from HPC centers, government labs, and academic institutions in D-Wave on-premises quantum systems for groundbreaking research and novel AI applications Company ...